Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised (Q37971458)

26 August 2017

Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised (English)

1 reference

26 August 2017

0 references

0 references

1

Anders M Fjell

1 reference

PubMed ID

22201015

26 August 2017

Kristine Beate Walhovd

series ordinal

2

object named as

Kristine B Walhovd

1 reference

26 August 2017

27 December 2011

1 reference

26 August 2017

20

1 reference

inferred from page(s)

published in

Molecular Neurobiology

1 reference

26 August 2017

45

1 reference

26 August 2017

153-172

1 reference

26 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s12035-011-8228-7

26 August 2017

0 references

cites work

Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century.

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Targeted proteomics in Alzheimer's disease: focus on amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

PET imaging of amyloid deposition in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic dystrophy type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The value of incomplete mouse models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid beta and APP as biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer's disease: progress in prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Neuroprotective therapeutics for Alzheimer's disease: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid-independent mechanisms in Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer's disease: a re-examination of the amyloid hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Are Abeta and its derivatives causative agents or innocent bystanders in AD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Neuropathology of older persons without cognitive impairment from two community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer neuropathologic alterations in aged cognitively normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Reimagining Alzheimer's disease--an age-based hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Loss of recent memory after bilateral hippocampal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Spatial representation in the entorhinal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Early detection of Alzheimer's disease using neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Healthy and pathological processes in adult development: new evidence from neuroimaging of the aging brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Atrophy rates accelerate in amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Regional rates of neocortical atrophy from normal aging to early Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Structural MRI biomarkers for preclinical and mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Longitudinal pattern of regional brain volume change differentiates normal aging from MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The cognitive neuroscience of remembering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Tracking Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Early marker for Alzheimer's disease: the atrophic hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The cortical signature of prodromal AD: regional thinning predicts mild AD dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Boosting power for clinical trials using classifiers based on multiple biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

A century of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Predicting MCI outcome with clinically available MRI and CSF biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid-β associated volume loss occurs only in the presence of phospho-tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Early detection of Alzheimer disease: ¹¹C-PiB PET in twins discordant for cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Brain atrophy in healthy aging is related to CSF levels of Aβ1-42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid-β associated cortical thinning in clinically normal elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Biomarkers predicting Alzheimer's disease in cognitively normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

One-year brain atrophy evident in healthy aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Larger temporal volume in elderly with high versus low beta-amyloid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Alzheimer's disease sends the wrong signals--a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

APP binds DR6 to trigger axon pruning and neuron death via distinct caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-011-8228-7

Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index

21 January 2018

1 reference

12 December 2020

Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease

1 reference

12 December 2020

Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease

1 reference

12 December 2020

Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia

1 reference

12 December 2020

High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation

1 reference

12 December 2020

Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta

1 reference

12 December 2020

Neuropathological hallmarks of Alzheimer's and Parkinson's diseases.

1 reference

12 December 2020

Relationship between atrophy and beta-amyloid deposition in Alzheimer disease

1 reference

12 December 2020

Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease

1 reference

12 December 2020

The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals

1 reference

12 December 2020

New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?

1 reference

12 December 2020

10.1007/S12035-011-8228-7

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22201015